NCT01094561 - Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

February 28, 2015

Study Completion Date

March 31, 2015

Conditions

Pancreatic Cancer

Interventions

DRUG

Synthetic Human Secretin

Subjects will each undergo a Secretin-Enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and a Secretin-Enhanced Endoscopic Ultrasound (S-EUS) evaluation, at a dose of 0.2 ucg/kg per exam. Synthetic Human Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.

PROCEDURE

Secretin-Enhanced Magnetic Resonance Cholangiopancreatography

PROCEDURE

Secretin-Enhanced Endoscopic Ultrasound

Trial Locations (1)

10032

Columbia University Medical Center, New York

All Listed Sponsors

lead

Elizabeth Hecht

OTHER